IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Brad C. Dunlap who wrote (30)	1/22/1997 5:32:00 PM
From: Richard Belanger	of 1762

Brad - In some of your earlier posts you mentioned that the patients receiving the Coulter treatment had to be hospitalized 2-3 days following treatment because of the Iodine-131. Do you know how much I-131 is typically administered for NHL? The Nuclear Regulatory Commission is in the process of finalizing a revised rule governing the release of patients with radiopharmaceuticals. The old rule contained a clause prohibiting a patient from being released until the activity in the body decreased to 30 millicuries or less. The new rule removes that requirement, and replaces it with a criterion related to how much radiation exposure other individuals (e.g., family members or breast-feeding infants) may receive if the patient is released. In essence, it gives the hospital much more flexibility in authorizing the release of patients. Obviously, this could have some impact on the selection of competing treatments. The new rule is due out in mid-Feb. I'll keep you posted on what I find out. Rich

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next